ADCETRIS® Development Collaboration

We are developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company.

Learn more

Collaboration Opportunities

If you are interested in learning
more about collaboration opportunities with Seattle Genetics, please contact our Business Development team. We are also actively evaluating potential in-licensing opportunities for cancer therapeutics.

Email Business Development,
or call 425-527-4000.

Expanding our opportunities through collaboration

Seattle Genetics has entered into multiple collaborations for its antibody-drug conjugate (ADC) technology with industry-leading biotechnology and pharmaceutical companies. There are currently 15 collaborator ADC programs in clinical development utilizing Seattle Genetics' technology. Our ADC technology licensing agreements have generated more than $250 million to date.

In addition to the financial benefit, these licensing activities extend the reach of our technology into additional programs through collaborator development. Additionally, in some cases, they provide us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates. We have two types of ongoing ADC collaborations:

ADC License Agreements

Under our ADC license agreements with AbbVie (formerly Abbott), Agensys, Bayer, Celldex, Daiichi-Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, Seattle Genetics is entitled to receive upfront payments, milestones and royalties on net sales of any resulting ADC products. We have the potential to receive more than $4.5 billion in future milestone payments across our ADC collaborations. Our licensees are responsible for all development, manufacturing and commercialization activities under these collaborations.

ADC Co-Development Agreements

Our ADC co-development agreements with Agensys and Genmab provide Seattle Genetics with opportunities to supplement our internal pipeline through opt-in rights to 50:50 co-development and profit-sharing for ADC product candidates. Under our Agensys deal, we are co-developing ASG-22ME and ASG-15ME. Through our Genmab deal, we have opt-in rights to one ADC program at completion of phase 1 clinical trials. Under this deal, if we do not opt-in, we are entitled to receive milestones and royalties on net sales of any resulting ADC product.

We have also formed a strategic collaboration with Oxford BioTherapeutics (OBT) to jointly discover novel ADCs for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project database. The antibodies generated by OBT will then be screened for activity using our ADC technology. The resulting ADCs may be selected by each company for further development and commercialization.

ADC COLLABORATOR PIPELINE

  Program Preclinical Phase 1 Phase 2 Pivotal/ Phase 3
Anti-GPNMB ADC
 
Breast cancer
     
Anti-CD79b
(RG7596, DCDS4501A)
 
Non-Hodgkin lymphoma
     
Anti-CD22
(RG7593, DCDT2980S)
 
Non-Hodgkin lymphoma
     
Anti-NaPi2b
(RG7599, DNIB0600A)
 
Ovarian cancer
     
Anti-STEAP1
(RG7450, DSTP3086S)
 
Prostate cancer
     
Anti-MUC16
(RG7458, DMUC5754A)
 
Ovarian cancer
     
Anti-ETBR
(RG7636)
 
Melanoma
     
RG7598
 
Multiple myeloma
     
RG7600
 
Pancreatic, ovarian cancer
     
Undisclosed ADCs
 
Cancer
     
Anti-PSMA ADC
 
Prostate cancer
     
Anti-AGS-16 ADC
 
Renal cell carcinoma
     
Undisclosed ADCs
 
Cancer
     
Anti-GCC ADC
 
Gastrointestinal malignancies
     
Anti-5T4 ADC
 
Solid tumors
     
Anti-EGFR ADC
 
Squamous cell tumors, glioblastoma
     
Undisclosed ADCs
 
Cancer
     
Undisclosed ADCs
 
Cancer
     
Undisclosed ADC
 
Solid tumors
     
Undisclosed ADCs
 
Cancer
     
Anti-TF ADC
 
Solid tumors
  Opt-in at end of phase 1  
ADCs
 
Cancer
Picking pool with opt-ins    
  Collaborator programs
with opt-ins

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com